SEQUENT — Sequent Scientific Balance Sheet
0.000.00%
- IN₹37.51bn
- IN₹42.33bn
- IN₹13.70bn
- 90
- 10
- 60
- 56
Annual balance sheet for Sequent Scientific, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2020 March 31st | 2021 March 31st | C2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | — | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,083 | 597 | 591 | 416 | 688 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3,597 | 3,785 | 3,624 | 3,779 | 3,754 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 7,041 | 7,136 | 7,832 | 7,899 | 8,229 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3,560 | 3,479 | 3,263 | 3,521 | 3,112 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 14,626 | 13,926 | 14,510 | 15,291 | 15,404 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4,947 | 4,609 | 5,121 | 5,261 | 6,270 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 7,755 | 6,649 | 7,589 | 8,303 | 8,838 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 6,871 | 7,277 | 6,921 | 6,988 | 6,566 |
Total Liabilities & Shareholders' Equity | 14,626 | 13,926 | 14,510 | 15,291 | 15,404 |
Total Common Shares Outstanding |